Arcellx, Intellia + Rewrite, Navitor + Janssen, ViiV

Dragons over unicorns, to CRISPR and beyond, spin-out-and-sell, and expanded approvals. 

Find out more at
https://LifeScienceTodayPodcast.com

Story References
Arcellx
Intellia + Rewrite
Navitor + Janssen
ViiV


About the Show
Life Science Today is your source for stories, insights, and trends across the life science industry. Expect weekly highlights about new technologies, pharmaceutical mergers and acquisitions, news about the moves of venture capital and private equity, and how the stock market responds to biotech IPOs. Life Science Today also explores trends around clinical research, including the evolving patterns that determine how drugs and therapies are developed and approved. It’s news, with a dash of perspective, focused on the life science industry.

Responses

THIS CONTENT IS FOR

Registered Users

Please login or register to continue.